Top Markets
Coin of the day
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
Rang in Aktien #5577
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Aktienkurs
$36.98
Zuletzt synchronisiert: 2026-08-26
Marktkapitalisierung
$2.58B
Veränderung (1 Tag)
-0.67%
Veränderung (1 Jahr)
55.51%
Land
NL
Handel Pharvaris N.V. (PHVS)

Kategorie

Dividendenrendite-Verlauf für Pharvaris N.V. (PHVS)
Dividendenrendite (TTM) von Pharvaris N.V. (Aktienkürzel: PHVS) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Pharvaris N.V. (PHVS) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH